Does the media prefer PACB or TXG?

In the previous week, 10x Genomics had 8 more articles in the media than Pacific Biosciences of California. MarketBeat recorded 10 mentions for 10x Genomics and 2 mentions for Pacific Biosciences of California. Pacific Biosciences of California's average media sentiment score of 0.93 beat 10x Genomics' score of 0.81 indicating that Pacific Biosciences of California is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pacific Biosciences of California 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive 10x Genomics 3 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer PACB or HBIO?

In the previous week, Pacific Biosciences of California and Pacific Biosciences of California both had 2 articles in the media. Harvard Bioscience's average media sentiment score of 0.94 beat Pacific Biosciences of California's score of 0.93 indicating that Harvard Bioscience is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pacific Biosciences of California 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Harvard Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend LMNX or PACB?

Pacific Biosciences of California has a consensus price target of $1.83, suggesting a potential upside of 35.80%. Given Pacific Biosciences of California's stronger consensus rating and higher possible upside, analysts clearly believe Pacific Biosciences of California is more favorable than Defiance Daily Target 2X Long LMND ETF. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Defiance Daily Target 2X Long LMND ETF 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Pacific Biosciences of California 2 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.80

Pacific Biosciences of California (PACB) Competitors

$1.35 -0.02 (-1.46%)

Closing price 06/11/2026 04:00 PM Eastern

Extended Trading

$1.38 +0.03 (+2.22%)

As of 06/11/2026 07:57 PM Eastern

Compare

PACB vs. TXG, HBIO, LMNX, TMO, and A

Should you buy Pacific Biosciences of California stock or one of its competitors? MarketBeat compares Pacific Biosciences of California with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Pacific Biosciences of California include 10x Genomics (TXG), Harvard Bioscience (HBIO), Defiance Daily Target 2X Long LMND ETF (LMNX), Thermo Fisher Scientific (TMO), and Agilent Technologies (A).

How does Pacific Biosciences of California compare to 10x Genomics?

Pacific Biosciences of California (NASDAQ:PACB) and 10x Genomics (NASDAQ:TXG) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability and risk.

10x Genomics has a net margin of -3.55% compared to Pacific Biosciences of California's net margin of -80.35%. 10x Genomics' return on equity of -2.86% beat Pacific Biosciences of California's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pacific Biosciences of California	-80.35%	-571.06%	-18.82%
10x Genomics	-3.55%	-2.86%	-2.23%

10x Genomics has higher revenue and earnings than Pacific Biosciences of California. 10x Genomics is trading at a lower price-to-earnings ratio than Pacific Biosciences of California, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pacific Biosciences of California	$160.01M	2.62	-$546.38M	-$0.43	N/A
10x Genomics	$642.82M	5.74	-$43.54M	-$0.17	N/A

Pacific Biosciences of California has a beta of 2.35, meaning that its share price is 135% more volatile than the broader market. Comparatively, 10x Genomics has a beta of 2.12, meaning that its share price is 112% more volatile than the broader market.

In the previous week, 10x Genomics had 8 more articles in the media than Pacific Biosciences of California. MarketBeat recorded 10 mentions for 10x Genomics and 2 mentions for Pacific Biosciences of California. Pacific Biosciences of California's average media sentiment score of 0.93 beat 10x Genomics' score of 0.81 indicating that Pacific Biosciences of California is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pacific Biosciences of California	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
10x Genomics	3 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

84.7% of 10x Genomics shares are held by institutional investors. 3.7% of Pacific Biosciences of California shares are held by company insiders. Comparatively, 8.8% of 10x Genomics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Pacific Biosciences of California currently has a consensus target price of $1.83, indicating a potential upside of 35.80%. 10x Genomics has a consensus target price of $23.17, indicating a potential downside of 20.25%. Given Pacific Biosciences of California's higher probable upside, analysts plainly believe Pacific Biosciences of California is more favorable than 10x Genomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pacific Biosciences of California	2 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.80
10x Genomics	1 Sell rating(s)	10 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.20

Summary

10x Genomics beats Pacific Biosciences of California on 12 of the 16 factors compared between the two stocks.

How does Pacific Biosciences of California compare to Harvard Bioscience?

Pacific Biosciences of California (NASDAQ:PACB) and Harvard Bioscience (NASDAQ:HBIO) are both small-cap life sciences tools & services companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability and risk.

In the previous week, Pacific Biosciences of California and Pacific Biosciences of California both had 2 articles in the media. Harvard Bioscience's average media sentiment score of 0.94 beat Pacific Biosciences of California's score of 0.93 indicating that Harvard Bioscience is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pacific Biosciences of California	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Harvard Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Pacific Biosciences of California has a beta of 2.35, meaning that its share price is 135% more volatile than the broader market. Comparatively, Harvard Bioscience has a beta of 1.53, meaning that its share price is 53% more volatile than the broader market.

Pacific Biosciences of California currently has a consensus target price of $1.83, indicating a potential upside of 35.80%. Harvard Bioscience has a consensus target price of $6.00, indicating a potential downside of 9.64%. Given Pacific Biosciences of California's higher probable upside, analysts plainly believe Pacific Biosciences of California is more favorable than Harvard Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pacific Biosciences of California	2 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.80
Harvard Bioscience	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Harvard Bioscience has lower revenue, but higher earnings than Pacific Biosciences of California. Pacific Biosciences of California is trading at a lower price-to-earnings ratio than Harvard Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pacific Biosciences of California	$160.01M	2.62	-$546.38M	-$0.43	N/A
Harvard Bioscience	$86.55M	0.35	-$56.70M	-$2.17	N/A

80.9% of Harvard Bioscience shares are held by institutional investors. 3.7% of Pacific Biosciences of California shares are held by company insiders. Comparatively, 20.3% of Harvard Bioscience shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Harvard Bioscience has a net margin of -11.44% compared to Pacific Biosciences of California's net margin of -80.35%. Harvard Bioscience's return on equity of -25.78% beat Pacific Biosciences of California's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pacific Biosciences of California	-80.35%	-571.06%	-18.82%
Harvard Bioscience	-11.44%	-25.78%	-4.37%

Summary

Harvard Bioscience beats Pacific Biosciences of California on 9 of the 14 factors compared between the two stocks.

How does Pacific Biosciences of California compare to Defiance Daily Target 2X Long LMND ETF?

Defiance Daily Target 2X Long LMND ETF (NASDAQ:LMNX) and Pacific Biosciences of California (NASDAQ:PACB) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, profitability, dividends, risk, analyst recommendations and media sentiment.

Defiance Daily Target 2X Long LMND ETF has a net margin of 5.39% compared to Pacific Biosciences of California's net margin of -80.35%. Defiance Daily Target 2X Long LMND ETF's return on equity of 4.66% beat Pacific Biosciences of California's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Defiance Daily Target 2X Long LMND ETF	5.39%	4.66%	2.91%
Pacific Biosciences of California	-80.35%	-571.06%	-18.82%

87.8% of Defiance Daily Target 2X Long LMND ETF shares are held by institutional investors. 6.6% of Defiance Daily Target 2X Long LMND ETF shares are held by insiders. Comparatively, 3.7% of Pacific Biosciences of California shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Pacific Biosciences of California has a consensus price target of $1.83, suggesting a potential upside of 35.80%. Given Pacific Biosciences of California's stronger consensus rating and higher possible upside, analysts clearly believe Pacific Biosciences of California is more favorable than Defiance Daily Target 2X Long LMND ETF.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Defiance Daily Target 2X Long LMND ETF	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Pacific Biosciences of California	2 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.80

In the previous week, Pacific Biosciences of California had 1 more articles in the media than Defiance Daily Target 2X Long LMND ETF. MarketBeat recorded 2 mentions for Pacific Biosciences of California and 1 mentions for Defiance Daily Target 2X Long LMND ETF. Defiance Daily Target 2X Long LMND ETF's average media sentiment score of 1.87 beat Pacific Biosciences of California's score of 0.93 indicating that Defiance Daily Target 2X Long LMND ETF is being referred to more favorably in the media.

Company	Overall Sentiment
Defiance Daily Target 2X Long LMND ETF	Very Positive
Pacific Biosciences of California	Positive

Defiance Daily Target 2X Long LMND ETF has a beta of -10.21, meaning that its stock price is 1,121% less volatile than the broader market. Comparatively, Pacific Biosciences of California has a beta of 2.35, meaning that its stock price is 135% more volatile than the broader market.

Defiance Daily Target 2X Long LMND ETF has higher revenue and earnings than Pacific Biosciences of California. Pacific Biosciences of California is trading at a lower price-to-earnings ratio than Defiance Daily Target 2X Long LMND ETF, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Defiance Daily Target 2X Long LMND ETF	$437.66M	0.01	$15.17M	$0.51	25.63
Pacific Biosciences of California	$160.01M	2.62	-$546.38M	-$0.43	N/A

Summary

Defiance Daily Target 2X Long LMND ETF beats Pacific Biosciences of California on 10 of the 16 factors compared between the two stocks.

How does Pacific Biosciences of California compare to Thermo Fisher Scientific?

Pacific Biosciences of California (NASDAQ:PACB) and Thermo Fisher Scientific (NYSE:TMO) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, profitability, media sentiment, risk, dividends, earnings and institutional ownership.

Thermo Fisher Scientific has a net margin of 15.15% compared to Pacific Biosciences of California's net margin of -80.35%. Thermo Fisher Scientific's return on equity of 16.86% beat Pacific Biosciences of California's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pacific Biosciences of California	-80.35%	-571.06%	-18.82%
Thermo Fisher Scientific	15.15%	16.86%	8.15%

89.2% of Thermo Fisher Scientific shares are held by institutional investors. 3.7% of Pacific Biosciences of California shares are held by insiders. Comparatively, 0.3% of Thermo Fisher Scientific shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Pacific Biosciences of California has a beta of 2.35, indicating that its share price is 135% more volatile than the broader market. Comparatively, Thermo Fisher Scientific has a beta of 0.88, indicating that its share price is 12% less volatile than the broader market.

In the previous week, Thermo Fisher Scientific had 39 more articles in the media than Pacific Biosciences of California. MarketBeat recorded 41 mentions for Thermo Fisher Scientific and 2 mentions for Pacific Biosciences of California. Thermo Fisher Scientific's average media sentiment score of 1.39 beat Pacific Biosciences of California's score of 0.93 indicating that Thermo Fisher Scientific is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pacific Biosciences of California	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Thermo Fisher Scientific	37 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive

Thermo Fisher Scientific has higher revenue and earnings than Pacific Biosciences of California. Pacific Biosciences of California is trading at a lower price-to-earnings ratio than Thermo Fisher Scientific, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pacific Biosciences of California	$160.01M	2.62	-$546.38M	-$0.43	N/A
Thermo Fisher Scientific	$44.56B	3.96	$6.70B	$18.19	26.12

Pacific Biosciences of California presently has a consensus target price of $1.83, indicating a potential upside of 35.80%. Thermo Fisher Scientific has a consensus target price of $608.95, indicating a potential upside of 28.17%. Given Pacific Biosciences of California's higher probable upside, equities research analysts clearly believe Pacific Biosciences of California is more favorable than Thermo Fisher Scientific.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pacific Biosciences of California	2 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.80
Thermo Fisher Scientific	0 Sell rating(s)	5 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.88

Summary

Thermo Fisher Scientific beats Pacific Biosciences of California on 14 of the 17 factors compared between the two stocks.

How does Pacific Biosciences of California compare to Agilent Technologies?

Pacific Biosciences of California (NASDAQ:PACB) and Agilent Technologies (NYSE:A) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, dividends, valuation, risk, profitability, earnings and analyst recommendations.

Agilent Technologies has higher revenue and earnings than Pacific Biosciences of California. Pacific Biosciences of California is trading at a lower price-to-earnings ratio than Agilent Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pacific Biosciences of California	$160.01M	2.62	-$546.38M	-$0.43	N/A
Agilent Technologies	$6.95B	5.26	$1.30B	$4.98	25.98

Pacific Biosciences of California has a beta of 2.35, suggesting that its share price is 135% more volatile than the broader market. Comparatively, Agilent Technologies has a beta of 1.26, suggesting that its share price is 26% more volatile than the broader market.

Pacific Biosciences of California presently has a consensus price target of $1.83, suggesting a potential upside of 35.80%. Agilent Technologies has a consensus price target of $160.93, suggesting a potential upside of 24.40%. Given Pacific Biosciences of California's higher probable upside, equities research analysts plainly believe Pacific Biosciences of California is more favorable than Agilent Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pacific Biosciences of California	2 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.80
Agilent Technologies	0 Sell rating(s)	3 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88

Agilent Technologies has a net margin of 19.55% compared to Pacific Biosciences of California's net margin of -80.35%. Agilent Technologies' return on equity of 24.33% beat Pacific Biosciences of California's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pacific Biosciences of California	-80.35%	-571.06%	-18.82%
Agilent Technologies	19.55%	24.33%	12.99%

In the previous week, Agilent Technologies had 17 more articles in the media than Pacific Biosciences of California. MarketBeat recorded 19 mentions for Agilent Technologies and 2 mentions for Pacific Biosciences of California. Agilent Technologies' average media sentiment score of 1.10 beat Pacific Biosciences of California's score of 0.93 indicating that Agilent Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pacific Biosciences of California	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Agilent Technologies	15 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Agilent Technologies beats Pacific Biosciences of California on 13 of the 15 factors compared between the two stocks.

Get Pacific Biosciences of California News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PACB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PACB vs. The Competition

Export

Metric	Pacific Biosciences of California	MED INSTRUMENTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$425.52M	$7.24B	$6.47B	$11.73B
Dividend Yield	N/A	1.21%	2.67%	5.56%
P/E Ratio	-3.14	48.13	24.43	24.35
Price / Sales	2.62	76.75	503.66	108.32
Price / Cash	1.74	25.01	43.20	54.62
Price / Book	67.50	6.91	10.50	6.82
Net Income	-$546.38M	$159.22M	$3.56B	$337.41M
7 Day Performance	-6.90%	-1.01%	0.23%	2.29%
1 Month Performance	5.47%	3.89%	0.67%	3.48%
1 Year Performance	14.41%	-0.45%	22.17%	27.16%

Pacific Biosciences of California Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PACB Pacific Biosciences of California	2.616 of 5 stars	$1.35 -1.5%	$1.83 +35.8%	+16.4%	$425.52M	$160.01M	N/A	730
TXG 10x Genomics	1.9308 of 5 stars	$29.18 -6.0%	$23.17 -20.6%	+169.5%	$3.94B	$642.82M	N/A	1,240	News Coverage
HBIO Harvard Bioscience	2.6071 of 5 stars	$6.01 -3.1%	$6.00 -0.2%	+14.8%	$27.94M	$86.55M	N/A	490
LMNX Defiance Daily Target 2X Long LMND ETF	N/A	$11.39 +7.8%	N/A	N/A	$3.76M	$437.66M	22.33	1,325	Gap Up
TMO Thermo Fisher Scientific	4.8905 of 5 stars	$469.41 -0.7%	$613.67 +30.7%	+14.4%	$175.70B	$44.56B	25.81	125,000	Positive News Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PACB) was last updated on 6/12/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Pacific Biosciences of California (PACB) Competitors

PACB vs. TXG, HBIO, LMNX, TMO, and A

How does Pacific Biosciences of California compare to 10x Genomics?

Summary

How does Pacific Biosciences of California compare to Harvard Bioscience?

Summary

How does Pacific Biosciences of California compare to Defiance Daily Target 2X Long LMND ETF?

Summary

How does Pacific Biosciences of California compare to Thermo Fisher Scientific?

Summary

How does Pacific Biosciences of California compare to Agilent Technologies?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PACB vs. The Competition

Pacific Biosciences of California Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Pacific Biosciences of California (PACB) Competitors

PACB vs. TXG, HBIO, LMNX, TMO, and A

How does Pacific Biosciences of California compare to 10x Genomics?

Is PACB or TXG more profitable?

Which has higher valuation and earnings, PACB or TXG?

Which has more volatility and risk, PACB or TXG?

Does the media prefer PACB or TXG?

Do insiders and institutionals hold more shares of PACB or TXG?

Do analysts recommend PACB or TXG?

Summary

How does Pacific Biosciences of California compare to Harvard Bioscience?

Does the media prefer PACB or HBIO?

Which has more volatility and risk, PACB or HBIO?

Do analysts recommend PACB or HBIO?

Which has higher valuation and earnings, PACB or HBIO?

Do insiders and institutionals hold more shares of PACB or HBIO?

Is PACB or HBIO more profitable?

Summary

How does Pacific Biosciences of California compare to Defiance Daily Target 2X Long LMND ETF?

Is LMNX or PACB more profitable?

Do insiders and institutionals have more ownership in LMNX or PACB?

Do analysts recommend LMNX or PACB?

Does the media prefer LMNX or PACB?

Which has more risk and volatility, LMNX or PACB?

Which has better earnings & valuation, LMNX or PACB?

Summary

How does Pacific Biosciences of California compare to Thermo Fisher Scientific?

Is PACB or TMO more profitable?

Do institutionals & insiders hold more shares of PACB or TMO?

Which has more volatility & risk, PACB or TMO?

Does the media prefer PACB or TMO?

Which has stronger earnings & valuation, PACB or TMO?

Do analysts rate PACB or TMO?

Summary

How does Pacific Biosciences of California compare to Agilent Technologies?

Which has higher valuation and earnings, PACB or A?

Which has more risk & volatility, PACB or A?

Do analysts rate PACB or A?

Is PACB or A more profitable?

Does the media favor PACB or A?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PACB vs. The Competition

Pacific Biosciences of California Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools